Bayer wins FDA ok for hemophilia drug

Aug 30, 2018

Bayer AG has received U.S. FDA approval for a Factor VIII hemophilia drug, called Jivi.

Jivi is used in preventative treatment of hemophilia A and is also approved for on-demand treatment. It is the third FDA-approved hemophilia A treatment in Bayer’s hemophilia portfolio.

Bayer has also submitted marketing authorization applications for Jivi in the European Union and Japan.

Read the press release

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!